UC San Diego Health's Moores Cancer Center in La Jolla, Calif., selected Tempus to provide molecular sequencing, clinical analysis and decision support tools.
Tempus, a health technology company focused on personalized oncology care, will collect and analyze clinical and molecular data to support Moores Cancer Center's research on immune checkpoint inhibitors across cancer types.
The company will also help the center incorporate genomic data into its clinical and research practices.
"Collecting and analyzing patients' molecular, treatment and outcome data will be transformative for patients, researchers and the healthcare ecosystem," said Eric Lefkofsky, co-founder and CEO of Tempus.